Results demonstrated disease modifying ability of T3D-959 in mild-to-moderate severity AD subjects (n=250), high pTau-217 ratio subgroup (pTau-217/Non-pTau-217 ratio ≥0.015, n=30) have shown 2 points improvement in ADAS-cog11 at 24wk which is better than anti-amyloid plaque antibodies at 76-78wks.
Along with identifying various blood biomarkers, establishing safety, PIONEER study also identified 30mg QD as the optimal dose for the further assessment during P-IIb/III study in m-to-m AD patients
T3D-959 is an oral brain-penetrating PPAR δ/ γ dual nuclear receptor agonist designed to improve both glucose and lipid metabolism dysfunction in AD
Ref: PR Newswire | Image: T3D Therapeutics
Related News:- Eisai and BioArctic Presented Results of Leqembi as Subcutaneous Dosage Form in P-III Trial for Alzheimer’s Disease CTAD 2023
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
